Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: To treat clitoral erectile dysfunction and improve vaginal and clitoral sexual response

Introduction: With the arrival of menopause, the lack of sexual steroids will promote a decrease in trophism and the ability to respond to the stimulation of erogenous zones. Based on the demonstrated regenerative effect of the Erbium Smooth laser, we proposed a novel laser protocol with sub-ablative Erbium:YAG in a Hyperstack pulse.

Materials / method: 13 physicians from 11 countries participated in this prospective study conducted between January 2019 and September 2022 (covid delays). 133 patients were recruited, with a mean age of 47,9 years. With an average BMI of 24.4 the 51% of the patients were under menopause. Three laser sessions with non-ablative erbium smooth laser were applied with 15 days interval with the new hyperstack technique.

Results: 13 physicians from 11 countries participated in this prospective study conducted between January 2019 and September 2022 (covid delays). 133 patients were recruited, with a mean age of 47,9 years. With an average BMI of 24.4 the 51% of the patients were under menopause. Three laser sessions with non-ablative erbium smooth laser were applied with 15 days interval with the new hyperstack technique.

Conclusion: Hyperstack Smooth mode Er:YAG laser is a new highly effective tool for the treatment of clitoral erectile dysfunction.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability